Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Peritoneal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1262Specimen Handling 924Magnetic Resonance Spectroscopy 829Carboplatin 821Cyclophosphamide 799Cisplatin 722Nivolumab 667Paclitaxel 627Radiotherapy 608Gemcitabine 570Biopsy 557Bevacizumab 478Dexamethasone 437fludarabine 407Docetaxel 377venetoclax 367Oxaliplatin 364Capecitabine 355Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 329Drug Therapy 325Doxorubicin 316Radiosurgery 314Standard of Care 309Blood Specimen Collection 308Pemetrexed 304Ipilimumab 298Radiation 285

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
soluble LAG-3 protein, human × 1 year × Clear all
NCT03625323 2026-04-22

TACTI-002

Immutep S.A.S.

Phase 2 Completed
187 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Immutep S.A.S.

Phase 3 Active not recruiting
756 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03252938 2026-02-19

INSIGHT

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 1 Active not recruiting
83 enrolled
GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT04811027 2025-12-11

TACTI-003

Immutep S.A.S.

Phase 2 Completed
171 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡